MetaADEDB 2.0 @ LMMD
Trimebutine
(LORDFXWUHHSAQU-UHFFFAOYSA-N)
Structure
SMILES
CCC(c1ccccc1)(N(C)C)COC(=O)c1cc(OC)c(c(c1)OC)OC
Type(s)
Approved
ATC code(s)
A03AA05
Molecular Formula:
C22H29NO5
Molecular Weight:
387.469
Log P:
3.7363
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
0
TPSA:
57.23
CAS Number(s):
39133-31-8
Synonym(s)
1.
Trimebutine
2.
Debridat
3.
Modulon
4.
Polibutin
5.
TM-906
6.
Transacalm
7.
Trimebutine Maleate
8.
Trimebutine Maleate Salt
9.
Maleate Salt, Trimebutine
10.
Maleate, Trimebutine
11.
Salt, Trimebutine Maleate
12.
TM 906
13.
TM906
External Link(s)
MeSHD014287
PubChem Compound5573
BindingDB83417
ChEBI94458
CHEMBLCHEMBL190044
DrugBankDB09089
DrugCentral2748
KEGGdr:D08639
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Abdominal PainOFFSIDES
2Abdominal adhesionsOFFSIDES
3Abdominal discomfortCanada Vigilance: 1Canada Vigilance
4AcidosisOFFSIDES
5Acute prerenal failureOFFSIDES
6AdenocarcinomaOFFSIDES
7AgraphiaOFFSIDES
8Alcohol poisoningOFFSIDES
9AlopeciaCanada Vigilance: 1Canada Vigilance
10Altered state of consciousnessOFFSIDES
11Ammonia increasedOFFSIDES
12Anal FissureOFFSIDES
13AngiokeratomaOFFSIDES
14AnorexiaOFFSIDES
15Anticholinergic SyndromeOFFSIDES
16AnuriaOFFSIDES
17AnxietyCanada Vigilance: 1Canada Vigilance
18ApathyOFFSIDES
19AscitesOFFSIDES
20Aspiration PneumoniaOFFSIDES
21AstheniaOFFSIDES
22Axonal neuropathyOFFSIDES
23Bacterial sepsisOFFSIDES
24Basophil percentage increasedOFFSIDES
25Biliary adenomaOFFSIDES
26Blood aldosterone increasedOFFSIDES
27Blood cholinesterase decreasedOFFSIDES
28Blood creatine phosphokinase increasedOFFSIDES
29Blood creatinine decreasedOFFSIDES
30Blood ethanol increasedOFFSIDES
31Blood fibrinogen increasedOFFSIDES
32Blood gastrin increasedOFFSIDES
33Blood ketone body increasedOFFSIDES
34Blood ketone body presentOFFSIDES
35Blood sodium increasedOFFSIDES
36Blood sodiumOFFSIDES
37Blood urea increasedOFFSIDES
38Brain natriuretic peptide increasedOFFSIDES
39BursitisOFFSIDES
40Cardiac TamponadeOFFSIDES
41Cell DeathOFFSIDES
42Cerebral calcificationOFFSIDES
43Chemotherapeutic drug level increasedOFFSIDES
44Chest wall cystOFFSIDES
45CholangiolitisOFFSIDES
46CholecystitisOFFSIDES
47Chronic ulcerative colitisOFFSIDES
48ClonusOFFSIDES
49ClumsinessOFFSIDES
50ColitisOFFSIDES
51Colonic Pseudo-ObstructionOFFSIDES
52Compression fractureOFFSIDES
53Concomitant disease progressionOFFSIDES
54ConfabulationOFFSIDES
55ContractureOFFSIDES
56CyanosisOFFSIDES
57Cystitis escherichiaOFFSIDES
58Cytolytic hepatitisOFFSIDES
59Cytomegalovirus testOFFSIDES
60DehydrationOFFSIDES
61Depressed Level of ConsciousnessOFFSIDES
62Diarrhea1930352
8112388		CTD
63DiplopiaOFFSIDES
64Disease recurrenceOFFSIDES
65DrowsinessOFFSIDES
66Drug abuserOFFSIDES
67Drug ineffectiveCanada Vigilance: 1Canada Vigilance
68Drug withdrawal headacheOFFSIDES
69Duodenal ObstructionOFFSIDES
70DuodenitisOFFSIDES
71DysphasiaOFFSIDES
72EczemaOFFSIDES
73Electrocardiogram ST segment abnormalOFFSIDES
74EnteritisOFFSIDES
75Eosinophilic PneumoniaOFFSIDES
76Epidermal growth factor receptor increasedOFFSIDES
77Febrile bone marrow aplasiaOFFSIDES
78FlatulenceOFFSIDES
79Gamma-Glutamyltransferase IncreasedOFFSIDES
80Gastrointestinal bacterial overgrowthCanada Vigilance: 1Canada Vigilance
81Gastrointestinal toxicityOFFSIDES
82General physical health deteriorationOFFSIDES
83GlobulinuriaOFFSIDES
84GlomerulonephritisOFFSIDES
85GlossitisOFFSIDES
86GranulocytosisOFFSIDES
87Gum neoplasm malignant stage unspecifiedOFFSIDES
88Heart sounds abnormalOFFSIDES
89Hepatitis COFFSIDES
90HepatitisOFFSIDES
91Histiocytosis haematophagicOFFSIDES
92HyperreflexiaOFFSIDES
93Ileal StenosisOFFSIDES
94Impaired work abilityCanada Vigilance: 1Canada Vigilance
95IncontinenceOFFSIDES
96Intestinal ObstructionOFFSIDES
97IntubationOFFSIDES
98Kidney FailureOFFSIDES
99Lactate pyruvate ratio increasedOFFSIDES
100Locked-In SyndromeOFFSIDES
101Lung AbscessOFFSIDES
102Lymphangiosis carcinomatosaOFFSIDES
103Lymphocyte count decreasedOFFSIDES
104Lymphocyte percentage decreasedOFFSIDES
105MegacolonOFFSIDES
106Muscle enzymeOFFSIDES
107NasopharyngitisOFFSIDES
108NauseaCanada Vigilance: 1Canada Vigilance
109NystagmusOFFSIDES
110ObstructionOFFSIDES
111OliguriaOFFSIDES
112Optic Disc EdemaOFFSIDES
113Oral fungal infectionOFFSIDES
114Oropharyngeal discomfortOFFSIDES
115PalpitationsCanada Vigilance: 1Canada Vigilance
116Pelvic fluid collectionOFFSIDES
117PericarditisOFFSIDES
118PeritonitisOFFSIDES
119PleurisyOFFSIDES
120Progesterone receptor assayOFFSIDES
121Protein total decreasedOFFSIDES
122Pustular psoriasisOFFSIDES
123PyelonephritisOFFSIDES
124QuadriparesisOFFSIDES
125Radiation mucositisOFFSIDES
126Radicular painOFFSIDES
127Regurgitation of foodOFFSIDES
128Renal cystOFFSIDES
129Renin increasedOFFSIDES
130Retinal Vein OcclusionOFFSIDES
131RhabdomyolysisOFFSIDES
132Sinus bradycardiaOFFSIDES
133Sjogren's SyndromeOFFSIDES
134Skin lesionOFFSIDES
135Skin neoplasm excisionOFFSIDES
136Small intestine carcinomaOFFSIDES
137Squamous cell carcinoma of skinOFFSIDES
138StridorOFFSIDES
139SubileusOFFSIDES
140Sudden onset of sleepOFFSIDES
141TremorCanada Vigilance: 1Canada Vigilance
142Urine sodium decreasedOFFSIDES
143VomitingCanada Vigilance: 1Canada Vigilance
144Weight decreasedCanada Vigilance: 1Canada Vigilance
145Wrong drug administeredOFFSIDES
146colonoscopyOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.